Quinuclidinone analogues as anticancer agents
US-2024217964-A1 · Jul 4, 2024 · US
US9790223B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9790223-B2 |
| Application number | US-201515125554-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2015 |
| Priority date | Mar 14, 2014 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A process for preparation of a compound of Formula (I) is disclosed.
Opening claim text (preview).
The invention claimed is: 1. A process for preparation of a compound of Formula (I), said process comprising: (a) reacting a compound of Formula (II) with trimethylsulfoxonium iodide to obtain a compound of Formula (III); wherein P 1 is H or an amine protecting group and P 2 is H or an alcohol protecting group; (b) reacting a compound of Formula (III) with O-benzyl hydroxylamine hydrochloride to obtain a compound of Formula (IV); wherein P 1 and P 2 are as defined above; (c) cyclizing a compound of Formula (IV) to obtain a compound of Formula (V); wherein P 1 and P 2 are as defined above; (d) reducing a compound of Formula (V) to obtain a compound of Formula (VI); wherein P 1 and P 2 are as defined above; (e) converting a compound of Formula (VI) to a compound of Formula (VII); wherein P 2 is as defined above; (f) cyclizing a compound of Formula (VII) to obtain a compound of Formula (VIII), optionally followed by diastereomeric separation; wherein P 2 is as defined above; (g) deprotecting a compound of Formula (VIII) to obtain a compound of Formula (IX); and (h) oxidizing a compound of Formula (IX), followed by sodium salt formation to obtain a compound of Formula (I). 2. The process according to claim 1 , wherein the P 1 is tert-butoxycarbonyl and P 2 is tert-butyldimethylsilyl. 3. The process according to claim 1 , wherein a compound of Formula (V) is obtained by cyclizing a compound of Formula (IV) in presence of a base selected from a group consisting of sodium hydride, potassium tert-butoxide and n-butyl lithium. 4. The process according to claim 1 , wherein a compound of Formula (VI) is obtained by reducing a compound of Formula (V) in presence of a reducing agent selected from a group consisting of sodium borohyride, sodium cyanoborohydride, sodium triacetoxyborohydride, sodium tripropanoyloxyborohydride and lithium borohydride. 5. The process according to claim 1 , wherein a compound of Formula (VII) is obtained by treating a compound of Formula (VI) with a deprotecting agent selected from a group consisting of hydrochloric acid, trifluoroacetic acid, hydrobromic acid, sulphuric acid, boron trifluoride etherate complex, piperidine, ammonia, methylamine, ammonium cerium (IV) nitrate and hydrogen source in presence of a transition metal catalyst. 6. The process according to claim 1 , wherein a compound of Formula (VIII) is obtained by cyclizing a compound of Formula (VII) in presence of a reagent selected from the group consisting of triphosogene, phosgene or carbonyldiimidazole. 7. The process according to claim 1 , wherein the diastereomeric separation of compound of Formula (VIII) is obtained by carrying out crystallization in a solvent selected from a group consisting of n-hexane, cyclohexane, heptanes, methyl alcohol, ethyl alcohol, isopropyl alcohol, water or a mixture thereof. 8. The process according to claim 1 , wherein sodium salt formation in step (h) is carried out in presence of sodium-2-ethyl hexanoate. 9. A process for preparation of a compound of Formula (I), said process comprising: (a) reacting a compound of Formula (II) with trimethylsulfoxonium iodide to obtain a compound of Formula (III); wherein P 1 is tert-butyloxycarbonyl and P 2 is tert-butyldimethylsilyl; (b) reacting a compound of Formula (III) with O-benzyl hydroxylamine hydrochloride to obtain a compound of Formula (IV); wherein P 1 and P 2 are as defined above; (c) cyclizing a compound of Formula (IV) in presence of potassium tert-butoxide to obtain a compound of Formula (V); wherein P 1 and P 2 are as defined above; (d) reducing a compound of Formula (V) in presence of sodium cyanoborohydride to obtain a compound of Formula (VI); wherein P 1 and P 2 are as defined above; (e) deprotecting a compound of Formula (VI) in presence of boron trifluoride etherate complex to obtain a compound of Formula (VII); wherein P 2 is as defined above; (f) cyclizing a compound of Formula (VII) in presence of triphosgene to obtain a compound of Formula (VIII), optionally followed by diastereomeric separation; wherein P 2 is as defined above; (g) deprotecting a compound of Formula (VIII) in presence of tetra n-butylammonium fluoride to obtain a compound of Formula (IX); and (h) oxidizing a compound of Formula (IX), followed by sodium salt formation to obtain a compound of Formula (I). 10. The compound of Formula (VIII) according to claim 9 , wherein P 2 is tert-butyldimethylsilyl, having diastereomeric purity of at least 99% as determined by HPLC
Bridged systems · CPC title
with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title
Nitrogen atoms (nitro radicals C07D211/38) · CPC title
by reaction of hydroxylamines with carbonyl compounds · CPC title
Compounds having Si-O-C linkages (Si-O-acyl linkages C07F7/1896) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.